GT Biopharma, Inc. — Form D/A

GT Biopharma, Inc. of SAN FRANCISCO, CA, a company, filed a Form D amendment with the SEC on 2020-07-23. $5.6M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (25)

NameRoleLocation
Anthony CataldoDirectorBeverly Hills, CA
Steven WeldonDirectorBeverly Hills, CA
Anthony CataldoExecutive OfficerBeverly Hills, CA
Anshuman DubeDirectorLas Vegas, NV
Michael BreenDirectorSAN FRANCISCO, CA
Michael BreenExecutive OfficerSAN FRANCISCO, CA
Alan UrbanExecutive OfficerSAN FRANCISCO, CA
Hilary KramerDirectorSAN FRANCISCO, CA
Charles CasamentoDirectorSAN FRANCISCO, CA
Andrew RitterDirectorSAN FRANCISCO, CA
Bruce WendelDirectorSan Francisco, CA
Rajesh ShrotriyaDirectorSan Francisco, CA
Steven WeldonExecutive OfficerBeverly Hills, CA
Kathleen J Clarence-SmithDirectorTAMPA, FL
Kathleen J Clarence-SmithExecutive OfficerTAMPA, FL
Anthony J CataldoDirectorTAMPA, FL
Jon B BonfiglioDirectorTAMPA, FL
Raymond B UrbanskiExecutive OfficerTAMPA, FL
Peter B KienerDirectorTAMPA, FL
Geoffrey B DavisDirectorTAMPA, FL
Kathleen Clarence-SmithDirectorWashington, DC
Kathleen Clarence-SmithExecutive OfficerWashington, DC
David SaloffDirectorBeverly Hills, CA
Kenneth EatonDirectorBeverly Hills, CA
Kenneth EatonExecutive OfficerBeverly Hills, CA

Other filings by this issuer (10)

FiledFormOfferingSold
2025-05-28D$20.0M
2025-05-27D$6.0M$6.0M
2025-03-07D$1.3M$1.3M
2020-06-12D$2.4M
2018-08-17D$5.1M$5.1M
2018-02-06D$7.1M$7.1M
2017-09-14D$4.5M$4.5M
2015-07-27D$1.5M$500K
2015-03-16D$3.0M$2.0M
2014-07-31D$1.4M$1.4M

More